WESTLEY CRUCES

Mr. WESTLEY CRUCES

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2017 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
AMAdelphe M Mfuh
Adelphe M Mfuh
BSBrett D Schneider
Brett D Schneider
WCWESTLEY CRUCES
WESTLEY CRUCES
OLOleg Larionov
Oleg Larionov

6 March 2023 in Natural Product Communications
Verified
Journal Article
Open access
ACArianna Collins
Arianna Collins
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay Tesfatsion
Tesfay Tesfatsion
KRKyle P Ray
Kyle P Ray
SCScott Caudill
Scott Caudill
WCWESTLEY CRUCES
WESTLEY CRUCES
The characterization of any compound is important in the field of chemistry. As the field of cannabinoid chemistry grows so does the need for the characterization of new cannabinoids or rare cannabinoids that gain popularity within the consumer and research fields. Hexahydrocannabinol (HHC) a hydrogenated analogue of Δ9-tetrahydrocannabinol (THC), also found in trace amounts naturally within the Cannabis sativa plant, has been gaining attention and popularity within the cannabis industry. Hexahydrocannabidiol (H4CBD) is a synthetic hydrogenated analogue to cannabidiol (CBD). Identifying the diastereomers of the cannabinoids with instrumentation plays a huge role within the chemistry field adding valuable information of the structure and the parameters for others to identify such cannabinoids. Elucidation and characterization of HHC and H4CBD were performed using current analytical techniques such as 1D and 2D nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), and gas chromatography-mass spectrometry (GC-MS), effectively characterizing both the diastereomers of HHC and H4CBD.

4 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MDMaite Loreto Docampo-Palacios
Maite Loreto Docampo-Palacios
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay T. Tesfatsion
Tesfay T. Tesfatsion
AOAlex Okhovat
Alex Okhovat
MPMonica Pittiglio
Monica Pittiglio
WCWESTLEY CRUCES
WESTLEY CRUCES
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure–activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.

27 September 2023 in Pharmacognosy Magazine
Verified
Journal Article
Open access
TTTesfay T. Tesfatsion
Tesfay T. Tesfatsion
GRGiovanni A. Ramirez
Giovanni A. Ramirez
MDMaite Loreto Docampo-Palacios
Maite Loreto Docampo-Palacios
ACArianna C. Collins
Arianna C. Collins
KRKyle P. Ray
Kyle P. Ray
WCWESTLEY CRUCES
WESTLEY CRUCES
Introduction: Cannabidiol (CBD) is one of many naturally biosynthesized compounds produced by Cannabis sativa. There is limited information available in the literature on hydrogenated CBD (tetrahydro cannabidiol or H4CBD) ( Adams et al., 1940b ). As hydrogenated derivatives of tetrahydrocannabinol (THC) and CBD become increasingly popular in consumer markets, toxicological assessments are vital in identifying toxic characteristics, if any, caused by hydrogenated cannabinoids. Objectives: Assessment of the preclinical toxicology of hydrogenated CBD is provided through the in vitro safety study of racemic H4CBD in hepatocytes, normal human lung fibroblasts (NHLF), and primary human neural progenitor (NPC) cell lines. The importance of these cell lines is related to major organs and is the primary focus in determining any major toxic characteristics when consuming products. The inclusion of the human ether-a-go-go related gene (hERG) patch clamp test, observes any inhibition of sodium and potassium ion channels related to the arrhythmia of the heart. Also, the AMES test was conducted to determine any carcinogenic characteristics that H4CBD might impose. Materials and Methods: Plated NHLF, hepatocytes, and NPC were used in a preclinical 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay for cytotoxicity observations with the visible color change of cellular use of formazan, while a plated AMES test was conducted to monitor any visible mutations within Escherichia coli for carcinogenic activity. Plated cloned HEK293 cells were given set voltages to determine ion channel activity to determine if H4CBD causes inhibition within these pathways, which would mimic any arrhythmia potential in cardiomyocytes. Results: Screening of the MTT assay had a median calculated 3.25 micromolar concentration where cell viability remained high in NHLF and NPC, with higher concentrations leading to decreased cell viability. A 3.25 micromolar concentration is also the median for hepatocytes, with a discrepancy in some of the data that could be accounted for by miscounting colonies. The hERG patch clamp test provided a zero net inhibition with values adding up to zero, determining that the compound did not inhibit normal processes within the ion channels of the plated HEK293 cells. The analysis of the different cell types revealed varying responses to H4CBD. NHLF exhibited a concentration-dependent reduction in cell viability, with sustained concentrations over 24 h at 6.25 µM resulting in a significant loss of viability. Conversely, hepatocytes showed a trend of decreased viability at longer exposure times and higher concentrations, but severe cytotoxicity was not observed. This suggests that hepatocytes are less susceptible to the cytotoxic effects of H4CBD compared to NHLF. In the hERG assay, H4CBD did not inhibit the action potentials within cardiomyocytes, indicating no inhibition of ion channels involved in cardiac function. This finding is important for assessing the potential cardiovascular effects of H4CBD. The AMES test results were negative, indicating that H4CBD did not demonstrate mutagenic activity in the tested strains. Conclusion: This supports the conclusion that H4CBD does not possess carcinogenic potential based on this assay. Both human NPC and NHLF showed a median concentration of 3.25 µM before exhibiting a significant reduction in cell viability. This information is valuable for determining research or consumer usage limits for H4CBD. It is important to note that this study represents a preclinical assessment, and further studies are required. The experimental design followed protocols typically used for preclinical assessments of novel pharmaceuticals. These findings provide insight into the cytotoxic effects of H4CBD and contribute to establishing research and safety parameters as these compounds continue to gain attention.

7 March 2024 in ACS Omega
Verified
Journal Article
Open access
GRGiovanni A. Ramirez
Giovanni A. Ramirez
TTTesfay T. Tesfatsion
Tesfay T. Tesfatsion
MDMaite L. Docampo-Palacios
Maite L. Docampo-Palacios
ICIvan Cruces
Ivan Cruces
AHAdam J. Hellmann
Adam J. Hellmann
WCWESTLEY CRUCES
WESTLEY CRUCES
Synthesizing tetrahydrocannabinol is a lengthy process with minimal yields and little applicability on an industrial scale. To close the gap between bench chemistry and industry process chemistry, this paper introduces a small-scale flow chemistry method that utilizes a microwave or ultrasonic medium to produce major tetrahydrocannabinol isomers. This process produces excellent yields and minimal side products, which leads to more efficient large-scale production of the desired cannabinoids.

31 May 2024 in ACS Omega
Verified
Journal Article
Open access
MPMonica K. Pittiglio
Monica K. Pittiglio
GRGiovanni A. Ramirez
Giovanni A. Ramirez
TTTesfay T. Tesfatsion
Tesfay T. Tesfatsion
KRKyle P. Ray
Kyle P. Ray
WCWESTLEY CRUCES
WESTLEY CRUCES
The 2018 Farm Bill dictates that delta-9-tetrahydrocannabinol (Δ9-THC) concentrations must not exceed 0.3% in hemp and hemp-derived products in order to be "compliant." This narrow margin of error necessitates very precise testing methods throughout every facet of the hemp industry. Though gas chromatography has become the industry's gold standard, many hemp laboratories still use high-performance liquid chromatography (HPLC) to quantify cannabinoids, and thus there exists a need for HPLC methods that can separate delta-8-tetrahydrocannabinol (Δ8-THC) and Δ9-THC-a notoriously difficult task. This article details one such method, while simultaneously acknowledging the inevitable limits of using HPLC to separate cannabinoids. The method was also used to test Δ8-THC samples that were marketed as compliant, and it was found that all of the samples contained well over 0.3% Δ9-THC. The use of refined testing methodologies is crucial for hemp companies to ensure compliance, prevent adverse health effects, and provide consumers with accurate cannabinoid profiles of the products that they purchase.